When there is no single best biological agent:: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents
When there is no single best biological agent:: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents
复制标题
DOI：
10.1111/j.1365-2230.2007.02673.x
复制
发表时间：
2008-03-01
影响因子：
4.1
通讯作者：
Gurer, M. A.
中科院分区：
文献类型：
--
作者：
Adisen, E.;Karaca, F.;Gurer, M. A.
新生物制剂的指南和治疗策略已经制定，但皮肤科医生在日常实践中采用这些指南时仍然面临困难。我们报告了一个银屑病和银屑病关节炎患者，其皮肤病变仅对依法利珠单抗有效，而关节炎对依那西普有效。该病例表明，即使在同一患者中，不同的生物制剂也可能获得不同的成功率。每种生物制剂都有不同的优点和缺点，有时很难为患者选择最好的单一制剂。银屑病通常成为最难治疗的疾病之一，并且对任何单一的抗银屑病剂都没有反应。也许在未来，将使用不同生物处理的旋转或组合处理。
Guidelines and treatment strategies for the new biological agents have been developed, but dermatologists continue to face difficulties in adopting these guidelines into their daily practices. We report a patient with psoriasis and psoriatic arthritis whose skin lesions responded only to efalizumab, and the arthritis to etanercept. This case shows that different biological agents may achieve different success rates even in the same patient. Each biological agent offers different advantages and disadvantages, which sometimes make it difficult to choose the single best agent for a patient. Psoriasis often becomes one of the most difficult diseases to treat and does not respond to any single antipsoriatic agent. Perhaps in the future, rotational or combination treatment with different biological treatments will be used.